Teva to appeal against invalidation of Copaxone patents

31-01-2017

Teva to appeal against invalidation of Copaxone patents

THPStock / shutterstock.com

Teva will appeal against a decision which saw the invalidation of four patents covering its multiple sclerosis drug Copaxone (glatiramer acetate injection).


Teva, Copaxone, patent, ANDA, FDA, patent infringement, appeal, Dr Reddy’s, Sandoz, Mylan

LSIPR